Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

/sup 212/Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy

Journal Article · · JNCI, J. Natl. Cancer Inst.; (United States)
For comparison of cytotoxicity from alpha-particle irradiation with that from conventional x-irradiation, /sup 212/Bi, an alpha-emitting radionuclide, was attached to a monoclonal antibody that recognizes a cell surface antigen on human pancreatic carcinoma cells. For a given level of survival, the /sup 212/Bi-antibody complex was found to be approximately 20 times more efficient in cell killing than x-irradiation and 5 times more cytotoxic when compared with the cytotoxicity of an antigen-negative cell line or an isotype-matched control antibody. High linear energy transfer radioimmunotherapy using alpha emitters linked to monoclonal antibodies may be useful in vivo and in vitro for selectively killing target cell populations, especially those resistant to other forms of treatment.
Research Organization:
National Cancer Institute, Bethesda, MD (USA)
OSTI ID:
7025669
Journal Information:
JNCI, J. Natl. Cancer Inst.; (United States), Journal Name: JNCI, J. Natl. Cancer Inst.; (United States) Vol. 80:6; ISSN JJIND
Country of Publication:
United States
Language:
English